Patents by Inventor Martial Ruat
Martial Ruat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9073835Abstract: The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to pharmaceutical compositions containing them.Type: GrantFiled: April 16, 2009Date of Patent: July 7, 2015Assignees: Centre National De La Recherche Scientifique, Universite De StrasbourgInventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Angèle Schoenfelder, André Mann, Maurizio Taddei, Antonio Solinas, Fabrizio Manetti
-
Patent number: 9061997Abstract: The present invention relates to compounds which are quinolinone derivatives of general formula (I) capable of modulating the activity, in particular of inducing the differentiation, of stem and progenitor cells; these compounds are of use in the treatment of disorders related to a stem differentiation defect; the invention also relates to novel compounds among these quinolinone derivatives and to pharmaceutical compositions containing the same.Type: GrantFiled: November 15, 2011Date of Patent: June 23, 2015Assignee: Centre National de la Recherche ScientifiqueInventors: Martial Ruat, Hélène Faure, Tatiana Gorojankina, André Mann, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
-
Patent number: 8981149Abstract: The invention relates to compounds of formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (I).Type: GrantFiled: September 21, 2012Date of Patent: March 17, 2015Assignees: Centre National de la Recherche Scientifique, Universite de StrasbourgInventors: Martial Ruat, Hélène Faure, Hermine Roudaut, Lucile Hoch, Angèle Schoenfelder, Maurizio Taddei, André Mann
-
Patent number: 8957091Abstract: The present invention relates to the use of quinolinone derivatives of general formula (I), ligands of the Smo receptor or of related receptors which target a binding site of the receptor which is different from the known ligand binding sites, as research tools for identifying modulators of the Smo receptor or of related receptors, characterizing the Hedgehog signalling pathway and diagnosis; the invention also relates to kits containing said derivatives of general formula (I).Type: GrantFiled: November 15, 2011Date of Patent: February 17, 2015Assignee: Centre National de la Recherche ScientifiqueInventors: Martial Ruat, Helene Faure, Tatiana Gorojankina
-
Patent number: 8889678Abstract: The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also relates to novel acyl guanidine derivatives as such.Type: GrantFiled: July 19, 2010Date of Patent: November 18, 2014Assignees: Centre National de la Recherche Scientifique, Universite de StrasbourgInventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Hermine Roudaut, André Mann, Angèle Schoenfelder, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
-
Publication number: 20140228441Abstract: The invention relates to compounds of formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (I).Type: ApplicationFiled: September 21, 2012Publication date: August 14, 2014Applicants: Centre National De La Recherche Scientifique, Universite De StrasbourgInventors: Martial Ruat, Hélène Faure, Hermine Roudaut, Lucile Hoch, Angèle Schoenfelder, Maurizio Taddei, André Mann
-
Patent number: 8703752Abstract: The invention relates to a novel use of compounds having formula (I), including mifepristone (RU 486 or RU 38 486) and the derivative salts thereof, for the preparation of a medicament that can modulate (activate or inhibit) the Hedgehog protein signalling pathway, which is intended for the treatment of pathologies involving a tissue dysfunction linked to deregulation of said pathway.Type: GrantFiled: January 22, 2004Date of Patent: April 22, 2014Assignee: Centre National de la Recherche ScientifiqueInventors: Martial Ruat, Elisabeth Traiffort, Hélène Faure
-
Publication number: 20130267559Abstract: The present invention relates to compounds which are quinolinone derivatives of general formula (I) capable of modulating the activity, in particular of inducing the differentiation, of stem and progenitor cells; these compounds are of use in the treatment of disorders related to a stem differentiation defect; the invention also relates to novel compounds among these quinolinone derivatives and to pharmaceutical compositions containing the same.Type: ApplicationFiled: November 15, 2011Publication date: October 10, 2013Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Martial Ruat, Helene Faure, Tatiana Gorojankina, Andre Mann, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
-
Publication number: 20130236912Abstract: The present invention relates to the use of quinolinone derivatives of general formula (I), ligands of the Smo receptor or of related receptors which target a binding site of the receptor which is different from the known ligand binding sites, as research tools for identifying modulators of the Smo receptor or of related receptors, characterizing the Hedgehog signalling pathway and diagnosis; the invention also relates to kits containing said derivatives of general formula (I).Type: ApplicationFiled: November 15, 2011Publication date: September 12, 2013Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Martial Ruat, Helene Faure, Tatiana Gorojankina
-
Publication number: 20120196865Abstract: The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also relates to novel acyl guanidine derivatives as such.Type: ApplicationFiled: July 19, 2010Publication date: August 2, 2012Applicants: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Hermine Roudaut, André Mann, Angèle Schoenfelder, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
-
Publication number: 20110275663Abstract: The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to pharmaceutical compositions containing them.Type: ApplicationFiled: April 16, 2009Publication date: November 10, 2011Inventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Angèle Schoenfelder, André Mann, Maurizio Taddei, Antonio Solinas, Fabrizio Manetti
-
Patent number: 7303895Abstract: The invention concerns the identification of a novel family of CTL (Choline Transporter Like) genes, in particular hCTL1 and hCTL2, involved in the metabolism and/or transport of choline in cells such as the intestinal tract cells, nervous cells, in particular motoneurons, sensitive neurons, neurons of the nucleus dorsalis of the spinal cord and oligodendrocytes. The invention opens up new prospects in particular for the treatment of familial dysautonomia, and Tangier disease. More generally, the identification of CTL genes enables to develop new strategies for treating diseases of the nervous system, in particular neurodegenerative demyelenating diseases, particularly Alzheimer disease, Parkinson disease and Huntington disease.Type: GrantFiled: November 3, 2000Date of Patent: December 4, 2007Assignee: Centre National de la Recherche Scientifique (CNRS)Inventors: Seana O'Regan, François Meunier, Elisabeth Traiffort, Martial Ruat
-
Publication number: 20070060546Abstract: The invention relates to a novel use of compounds having formula (I), including mifepristone (RU 486 or RU 38 486) and the derivative salts thereof, for the preparation of a medicament that can modulate(activate or inhibit) the Hedgehog protein signalling pathway, which is intended for the treatment of pathologies involving a tissue dysfunction linked to deregulation of said pathway.Type: ApplicationFiled: January 22, 2004Publication date: March 15, 2007Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFInventors: Martial Ruat, Elisabeth Traiffort, Helene Faure
-
Patent number: 7157498Abstract: The invention concerns diamines of general formula (I), wherein: A represents a group A1 or A2 of general formula (II); B represents a group B1 or B2 of general formula (III); X represents a SO2, CH2, C?O or COO; YZ represents a group of formula CH(R25)—CH(R26) or CH(R27)?(R28), and R1 to R28, identical or different, represent independently of one another, a hydrogen or halogen atom or an alkyl, cycloalkyl, CN, NO2, hydroxy, aryl, aralkyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, arylalkylamino, diarylamino diarylalkylamino, trihalogenoalkyl or trihalogenoalkoxy group, provided that in the group A1, at least one of the radicals R1, R2, R3, R4 or R5 represents the hydrogen atom when the other four do not represent the hydrogen atom and in the group B1, at least one of the radicals R13, R14, R15, R16 or R17 represents the hydrogen atom when the other four do not represent the hydrogen atom, and their salts with a pharmaceutically acceptable acid, in the form of racemic mixtuType: GrantFiled: August 7, 2001Date of Patent: January 2, 2007Assignee: Centre National de la Recherche Scientifique (CNRS)Inventors: Philippe Marcel Dauban, Robert Hugh Dodd, Helene Veronique Faure, Martial Ruat, Pierre Jean-Paul Potier, Albane Kessler
-
Patent number: 7084167Abstract: The invention concerns compounds of general formula (I) wherein: the group X represents a —NR4, —CH?N or —CHR5-NR4-group; the group Y represents an oxygen or sulphur atom or a NR, —CR5, —CHR5-, —CR5=CR6- or —CHR5-CHR6 group provided that when group X represents the —CH?N— or —CHR5-NR4-group, group Y represents an oxygen or a sulphur atom or a Nr, —CR5 or —CHR group; the group R represents a hydrogen atom or an alkyl, aryl or aralkyl group; the groups R1, R5 and R6, identical or different, represent each a hydrogen or halogen atom or an alkyl or alkoxy group; the group R2 represents a hydrogen atom or an alkyl group; the group R3 represents an aryl group; and the group R4 represents a hydrogen atom, an alkyl, aryl, aralkyl, alkylsulphonamide, arylsulphonamide or aralkylsulphonamide group; and their salt with a pharmaceutically acceptable acid, in the form of a racemic mixture and their optically pure isomer.Type: GrantFiled: May 23, 2001Date of Patent: August 1, 2006Assignee: Centre National de la Rechereche Scientifique (CNRS)Inventors: Martial Ruat, Robert Dodd, Hélène Véronique Faure, Philippe Marcel Dauban, Albane Kessler, Pierre Jean-Paul Potier
-
Publication number: 20050192317Abstract: The invention concerns diamines of general formula (I), wherein: A represents a group A1 or A2 of general formula (II); B represents a group B1 or B2 of general formula (III); X represents a SO2, CH2, C?O or COO; YZ represents a group of formula CH(R25)—CH(R26) or CH(R27)?(R28), and R1 to R28, identical or different, represent independently of one another, a hydrogen or halogen atom or an alkyl, cycloalkyl, CN, NO2, hydroxy, aryl, aralkyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, arylalkylamino, diarylamino diarylalkylamino, trihalogenoalkyl or trihalogenoalkoxy group, provided that in the group A1, at least one of the radicals R1, R2, R3, R4 or R5 represents the hydrogen atom when the other four do not represent the hydrogen atom and in the group B1, at least one of the radicals R13, R14, R15, R16 or R17 represents the hydrogen atom when the other four do not represent the hydrogen atom, and their salts with a pharmaceutically acceptable acid, in the form of racemic mixtuType: ApplicationFiled: August 7, 2001Publication date: September 1, 2005Inventors: Philippe Dauban, Robert Dodd, Helene Faure, Martial Ruat, Pierre Potier, Albane Kessler
-
Publication number: 20030199497Abstract: The invention concerns compounds of general formula (I) wherein: 1Type: ApplicationFiled: April 24, 2003Publication date: October 23, 2003Inventors: Martial Ruat, Robert Dodd, Helene Veronique Faure, Philippe Marcel Dauban, Albane Kessler, Pierre Jean-Paul Potier
-
Patent number: 6159707Abstract: The present invention provides a nucleic acid comprising a sequence that encodes a sperm receptor that is related to, but is different from, a receptor of the odorant receptor family. The present invention also provides a method of obtaining a nucleic acid that comprises a sequence that encodes a sperm receptor, as well as a means of using the elements of the invention in a method of contraception, a method of detecting autoimmune infertility, and a method of affecting fertility.Type: GrantFiled: November 8, 1996Date of Patent: December 12, 2000Assignee: Johns Hopkins University School of MedicineInventors: Gabriele V. Ronnett, Loren Walensky, Martial Ruat, Solomon H. Snyder